Grand Brilliance Group Holdings (HKSE:08372) Debt-to-EBITDA : 0.26 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Grand Brilliance Group Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Grand Brilliance Group Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was HK$2.40 Mil. Grand Brilliance Group Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was HK$0.00 Mil. Grand Brilliance Group Holdings's annualized EBITDA for the quarter that ended in Sep. 2023 was HK$9.35 Mil. Grand Brilliance Group Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 0.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Grand Brilliance Group Holdings's Debt-to-EBITDA or its related term are showing as below:

HKSE:08372' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06 Med: 0.35 Max: 0.45
Current: 0.24

During the past 8 years, the highest Debt-to-EBITDA Ratio of Grand Brilliance Group Holdings was 0.45. The lowest was 0.06. And the median was 0.35.

HKSE:08372's Debt-to-EBITDA is ranked better than
82.67% of 75 companies
in the Medical Distribution industry
Industry Median: 2 vs HKSE:08372: 0.24

Grand Brilliance Group Holdings Debt-to-EBITDA Historical Data

The historical data trend for Grand Brilliance Group Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Brilliance Group Holdings Debt-to-EBITDA Chart

Grand Brilliance Group Holdings Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.06

0.38

0.45

0.32

Grand Brilliance Group Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.69	-	0.30	-	0.26

Competitive Comparison of Grand Brilliance Group Holdings's Debt-to-EBITDA

For the Medical Distribution subindustry, Grand Brilliance Group Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grand Brilliance Group Holdings's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Grand Brilliance Group Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Grand Brilliance Group Holdings's Debt-to-EBITDA falls into.

Grand Brilliance Group Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Grand Brilliance Group Holdings's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3.766	+	0.688)	/	13.895
	=	0.32

Grand Brilliance Group Holdings's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.403	+	0)	/	9.348
	=	0.26

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

Grand Brilliance Group Holdings (HKSE:08372) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Grand Brilliance Group Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Grand Brilliance Group Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Brilliance Group Holdings (HKSE:08372) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Grand Brilliance Group Holdings Ltd (HKSE:08372) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Sha Tsui Road, The Octagon, Units 2901-2903 and 2905, 29th Floor, New Territories, Tsuen Wan, Hong Kong, HKG

Website

http://www.grandbrilliancegroup.com

Grand Brilliance Group Holdings Ltd is an investment holding. The company is engaged in the business of medical device distribution. The company also provides one-stop medical device solutions, including market trend analysis, sourcing of medical devices, after-sale services, technical support, and training services, medical device leasing services, and quality assurance. Geographically, the company derives revenue from Hong Kong. The company serves private hospitals, public hospitals, private clinics, non-profit organizations, universities, and individual end-users in Hong Kong.

Grand Brilliance Group Holdings (HKSE:08372) Headlines

No Headlines